viropharma

und sie verdienen sogar echtes GELD...


ViroPharma Swings To 1Q Profit On Strong Vancocin Sales
                          
§
05-03-05 04:43 PM EST

EXTON, Pa. (Dow Jones)--ViroPharma Inc. (VPHM) swung to a first-quarter profit, helped by strong Vancocin antibiotic sales, revenue associated with a license agreement that was recognized during the quarter and a gain related to the company's senior notes.

In a press release Tuesday, the pharmaceutical company said it earned a first- quarter profit of $17.4 million, or 36 cents a share, reversing a loss of $16.6 million, or 63 cents a share, a year earlier.

Latest results included a $3.6 million gain on the change in the fair value of the derivative liability related to the make-whole provision of the company's senior convertible notes.

The company's year-ago loss included $9.3 million of costs as the result of the January 2004 restructuring.

First-quarter revenue surged to $27.2 million from $1.74 million a year ago.

During the quarter, ViroPharma booked $21.1 million of Vancocin sales and recognized $6 million in revenue during the quarter from the sale of inventory to Schering-Plough related to its 2004 license agreement.

First-quarter research and development expenses fell to $2.8 million from $8.4 million a year earlier, mainly due to restructuring charges and transition- related costs of $5 million that were booked in the year-ago quarter.

For 2005, ViroPharma said it now expects net product sales of $74 million to $ 79 million, with $12 million to $13 million in cost of sales. The 2005 projection represents growth of 37% to 46% from unaudited product sales of Vancocin in 2004.

In March, the company had expected new product sales of $62 million to $66 million for the year. Also at the time, ViroPharma estimated 2005 costs of sales of $20 million to $24 million, which included $9 million to $10.5 million in royalties to Eli Lilly & Co. (LLY).

The current guidance doesn't include these royalties in cost of sales. The company said it intends to book future royalty payments as contingent consideration and will record an adjustment to the carrying amount of the related intangible asset and a cumulative adjustment to the intangible amortization upon achievement of the related sales milestones.

The company also expects to be cash flow positive from operating activities in 2005.

ViroPharma plans to host a conference call Wednesday at 10:00 a.m. EDT.

ViroPharma Inc. - Exton, Pa.
  1st Quar March 31:
                       2005             2004
Revenue              $27,196,000       $1,737,000
Net income          a 17,374,000    b (16,616,000)
Avg shrs (diluted)    51,997,000       26,424,000
Shr earns
Net income                a .36           b (.63)

a. Includes a $3.6 million gain on the change in the fair value of the derivative liability related to the make-whole provision of the company's senior convertible notes.

b. Includes restructuring costs of $9.3 million.

Company Web site: http://www.viropharma.com

 

 

13-Jun-05 TARNOFF, JOSHUA M.
Vice President 1,500 Direct Purchase at $6.60 per share. $9,900
 10-Jun-05§CLAYPOOL, WILLIAM D. MD
  Director    10,000    Direct§Purchase at $5.73 - $5.78 per share. $58,0002
  6-Jun-05§GLASER, ROBERT J.
  Director    12,500    Direct§Purchase at $5.4784 per share. $68,480
 26-May-05§CLAYPOOL, WILLIAM D. MD
  Director    10,000    Direct§Purchase at $4.10 per share. $41,000
 26-May-05§DOYLE, THOMAS F.
General Counsel 5,000 Direct Purchase at $3.77 - $3.9 per share. $19,0002
 19-May-05§GLASER, ROBERT J.
  Director     7,500    Direct§Purchase at $3.76 per share. $28,200
 12-May-05§DE ROSEN, MICHEL
Chief Executive Officer 28,500 Direct Purchase at $3.4755 - $3.5464 per share. $100,0002
 11-May-05§BROOKE, PAUL A.
  Director   126,500    Direct§Purchase at $3.121 per share. $394,806  

ViroPharma dabei bleiben

Die Aktien hätten bis auf neue Jahreshochs von 7,20 USD zugelegt. Von einer kurzfristigen technischen Verschnaufpause in der Vorwoche abgesehen scheine die Aktie auch noch recht weit davon entfernt zu sein, die Rallye auslaufen zu lassen, auch wenn die Technik mittlerweile natürlich schon ein wenig heiß zu laufen drohe.

Die Sorgen, dass die großvolumige Ausübung der 6 Prozent-Wandelanleihe im Markt in Bezug auf Verwässerung und möglichen Abgabedruck Spuren hinterlassen würde, hätten sich jedenfalls auf ein Minimum verringert. Ein Grund dafür sei ein durchaus genialer Schachzug des Unternehmens. Statt sich die Ausübung durch die Bond-Inhaber stückweise vorschreiben zu lassen sei das Unternehmen zum Gegenangriff übergegangen und habe für ein Volumen von 18,75 Mio. USD die zwangsweise Wandlung in Aktien der Gesellschaft erklärt. Nach Ansicht der Wertpapierexperten sei das ein brillanter Konter gewesen. Dieser sei mit der Meldung perfektioniert worden, dass weitere 12,2 Mio. USD der Wandelanleihe zurückgekauft worden seien. Mit diesem Schachzug habe ViroPharma die ausstehenden Verbindlichkeiten aus nachrangigen Notes und Wandelanleihen auf 86,7 Mio. USD nach unten schrauben und jährliche Zinskosten von 1,4 Mio. USD einsparen können.

Vor diesem Hintergrund sei es zu Insiderkäufen gekommen. So hätten William Claypool und Joshua Tarnoff Mitte des Monats für insgesamt 67.331 USD weitere ViroPharma-Aktien erworben. In der Spitze seien Käufe zu Kursen bis 6 USD erfolgt.

Die Experten von "Hot Stocks Investor" raten bei der ViroPharma-Aktie dabei zu bleiben. Analyse-Datum: 28.06.2005

Analyst: Hot Stocks Investor

Quelle:Aktien & Co  28/06/2005 12:17

**********************************************


ViroPharma echtes Schnäppchen (Frankfurter Tagesdienst)

Die Experten vom "Frankfurter Tagesdienst" halten die Aktie von ViroPharma (ISIN US9282411084/ WKN 903906) für echtes Schnäppchen und noch weit von ihren Höchstkursen entfernt.

Der Konzern sei der Turnaround der Woche. Das Biotech-Unternehmen habe sich auf die Erforschung viraler Erkrankungen im Bereich der Atemwege und Hepatitis konzentriert. Das erste Präparat Vancocin sei schon am Markt und übertreffe alle Erwartungen.

Im ersten Quartal hätten die Optimisten 16,4 Mio. USD Erlös in Aussicht gestellt. Tatsächlich seien es aber 20 Mio. USD gewesen. Damit sei Vancocin Hauptumsatzträger bei ViroPharma gewesen. Die gesamten Erlöse seien im ersten Quartal von 1,7 auf 27,2 Mio. USD geklettert. Wobei der Sprung in die schwarzen Zahlen mit 17,4 Mio. USD (man solle die Marge beachten) gelungen sei.

Der starke Verkauf laufe weiter: Die Aprilzahlen würden die höchsten Absätze in der Geschichte zeigen. Für 2005 würden nun Umsätze von 74 bis 79 Mio. USD angepeilt. Die Experten würden mindestens 90 Mio. USD erwarten.

Mit einem KGV von 9,0 ist die Aktie von ViroPharma für die Experten vom "Frankfurter Tagesdienst" ein echtes Schnäppchen und noch weit von ihren Höchstkursen entfernt. Das Stop-buy-Limit sollte bei 7,40 USD und das Stop-loss-Limit bei 6,12 USD platziert werden. Analyse-Datum: 27.06.2005

Analyst: Frankfurter Tagesdienst
KGV: 9.0
Rating des Analysten:


Quelle:Aktien & Co  27/06/2005 17:42

 

to whom it may concern....



>6%+ an der nasdaq heut abend ist ok... das volumen könnte aber etwas höher sein.


but the trend is....

gute nacht, vor allem an die stillen mitgeniesser

ciao

;->>

 

   

 

ViroPharma to Release 2005 Second Quarter and Six Month Financial Results on August 2, 2005: Conference Call to Discuss Results to Be Held at 10:00 A.M. on August 3, 2005

schätze, je nachdem wie die ausfallen könnte es kräftige auf- oder abschläge geben...


ciao

tl  

ViroPharma Incorporated Reports Second Quarter and Six-Month 2005 Financial Results
Tuesday August 2, 5:04 pm ET
Company Reports Record Revenue; Increases Guidance for 2005


Net sales of Vancocin(r) were a record $28.8 million for the second quarter of 2005 and $49.9 million for the first six months of 2005. Operating income in the second quarter and six months of 2005 was $18.7 million and $36.1 million, respectively, compared to operating losses in the second quarter and six months of 2004 of $3.6 million and $18.5 million, respectively. The increases in operating results from 2004 to 2005 were driven primarily by sales of Vancocin and the related cost of sales.

Net income improved over the second quarter and six-months of 2004 to $5.0 million and $22.4 million, respectively, compared to a net loss of $5.4 million and $22.0 million for the same periods in 2004. Net income per share for the quarter ended June 30, 2005 was $0.15 per share, basic, and $0.11 per share, diluted, compared to a net loss of $0.20 per share, basic and diluted, for the same period in 2004. Net income per share for the six-months ended June 30, 2005 was $0.75 per share, basic, and $0.44 per share, diluted, compared to a net loss of $0.83 per share, basic and diluted, for the same period in 2004. The primary drivers of the change from net loss in 2004 to net income in 2005 were the effects of improved operating income , partially offset by debt-related costs and income tax expense in 2005.

``We are very proud of our financial endeavors during the second quarter of 2005, particularly as it relates to the continued performance of Vancocin; prescriptions for the product were up 39% over the same period last year, and up 30% over the first quarter of 2005,'' commented Michel de Rosen, ViroPharma's chief executive officer. ``During the quarter, thanks to the performance of Vancocin, we were able to improve our operating income over the first quarter of 2005, and make significant improvements to our capital structure, as we reduced the principal amount of our debt by $97.6 million through the end of June 2005. Following the end of the quarter, we have reduced our debt even further, and as of today have only $86.7 million in outstanding debt. In addition to our operating momentum, we are also proud of our continued progress in our clinical programs.''

Operating Highlights

Net sales of Vancocin were $28.8 million and $49.9 million for the first three and six-months of 2005, driven by prescription demand and price increases. Prescriptions increased 31% for the first six months of 2005 compared to the first six months of 2004. Additionally, net sales of Vancocin increased 37% over the first quarter of 2005, primarily resulting from the increase in prescriptions and the effect of the price increase realized beginning in April 2005. There were no comparable net sales in the 2004 periods, as the company acquired Vancocin from Eli Lilly and Company in November 2004.

The six-month 2005 period also included $6.0 million in revenue from the sale of inventory to Schering-Plough pursuant to the license agreement between the companies.

The gross margin rate (net product sales less cost of sales as a percent of net product sales) for Vancocin increased in the second quarter of 2005 to 85% from 83% in the first quarter of 2005, primarily due to the April 2005 price increase. The gross margin rate was 84% for the six-months ended June 30, 2005.

The total costs and expenses associated with operating income (loss) were $10.3 million and $5.4 million, for the second quarter of 2005 and 2004, respectively, and $20.1 million and $22.0 million, for the six-months of 2005 and 2004, respectively. These changes reflect the net effect of increases related to the Vancocin cost of sales and intangible amortization and decreases related to research and development and marketing, general and administration expenses. These changes primarily resulted from the Company's purchase of Vancocin and the results of the Company's January 2004 restructuring, which included $9.3 million of costs recorded in the six months ended June 30, 2004.

For the first time since inception, the Company recorded a $3.8 million income tax expense in the second quarter of 2005, which is based on a combined federal and state estimated annual effective tax rate of 15%. This resulted from the Company's preliminary study on the availability of net operating loss carryforwards, which indicates that, assuming the Company is profitable, it should be able to utilize all carryforwards over future years, but with annual limitations. As such, the Company believes that taxable income will exceed available carryforwards for 2005.

Regarding additional payments due to Lilly in connection with the Vancocin acquisition, net sales as of June 30, 2005 exceeded the minimum net sales threshold of $44.0 million by approximately $6.0 million and the Company recorded additional purchase price of $2.9 million to intangible assets in June 2005 and established a corresponding liability to be paid in the third quarter of 2005.

Debt Highlights

During the second quarter of 2005, the Company recorded a charge of $7.6 million for the change in fair value of derivative liability that relates to the make-whole provision on the senior convertible notes, which are no longer outstanding. This change in the second quarter resulted in a charge of $4.0 million for the first six-months of 2005.

The Company recorded a $1.2 million net gain related to the repurchase of $41.2 million of subordinated convertible notes for $39.8 million in the second quarter of 2005. The net gain is comprised of the gross gain of $1.4 million less the write-off of $0.2 million of deferred finance costs.

The increases in both periods for interest expense were due to the interest, amortization of financing costs, and debt discount from the senior convertible notes, issued in January and April 2005. Interest expense also includes the $0.6 million related to the beneficial conversion feature for the auto-conversion of the senior convertible notes in June 2005.

During the second quarter of 2005, the initial investors in the senior notes exercised their purchase option and acquired an additional $12.5 million of the senior convertible notes. In addition, the Company reduced the debt principal by $97.6 million through $41.2 million of purchases of convertible subordinated notes and by $56.4 million as a result of conversions of senior convertible notes. The Company had $102.1 million in principal amount of notes outstanding as of June 30, 2005, which was further reduced by $15.4 million in July 2005 as a result of the Company affecting an auto-conversion on the remaining senior convertible notes. As of July 12, 2005, the senior convertible notes were no longer outstanding.

Cash Highlights

As of June 30, 2005, ViroPharma assets included approximately $39.9 million in cash, cash equivalents and short-term investments, which represents a $4.3 million decrease from December 31, 2004. This decrease is primarily the net result of cash used of $46.6 million on repurchases of convertible subordinated notes and make-whole payments on the senior convertible notes and cash received for the $12.5 million related to the exercise of the purchase option by the holders of the senior convertible notes in April 2005. In addition, Vancocin sales increased net cash.

Looking ahead in 2005

ViroPharma is updating its previously announced guidance for the year 2005 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a complete discussion and disclosure of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below. The Company's guidance does not include non-operating expenses or income.

For the year 2005, ViroPharma expects the following:


 --  Net product sales:  $100 to $105 million, representing growth
     of 85% to 94% over unaudited net product sales of Vancocin
     in 2004;

 --  Cost of sales:  $15 to $17 million;

 --  Research and Development:  $11.5 to $14.5 million;

 --  Marketing, General and Administrative:  $10 to $13 million;

 --  Net cash flows provided by operations:  At least $40 million.
 

selbst WENN vancocin gemeint ist: barriers are high... außerdem wird das dauern. kurzfristig seh ich somit keine probleme.



ViroPharma Stock Falls on Generic Worries; Analysts Says Barriers High for Rival Drug

NEW YORK (AP) -- Shares of Viropharma Inc. dropped more than 14 percent Thursday as the specter of generic competition for the drug maker's major antibiotic overshadowed promising study results for an experimental hepatitis C therapy.

ADVERTISEMENT
Late Wednesday, Piper Jaffray analyst Thomas Wei said in a report that a drug development deal between Akorn Inc., a specialty pharmaceutical firm, and an Indian drug manufacturer could be the first attempt to develop a generic version of Vancocin, an antibiotic that has boosted Viropharma's sales since it bought the drug from Eli Lilly & Co. in December. The drug lost its patent protection before Viropharma bought it.

Akorn and India's Cipla Ltd. said only that their collaboration is for a generic version of an oral anti-infective drug that is primarily used in U.S. hospitals and has market size of about $100 million.

"Given the description of the product that they gave, it's a pretty good chance that it's Vancocin," said JMP Securities analyst Adam Cutler. "That's the only one that comes to mind" that fits the description, he said.

Viropharma shares fell $3.85, or 18 percent, to $18.11 in Nasdaq trading. The drop came even as Viropharma said its HCV-796 drug reduced hepatitis C virus levels in an early, Phase I study. The Exton, Pa.-based company is developing the therapy, designed to interfere with virus replication, with drug maker Wyeth.

Still, Wei and Cutler both said there are significant barriers to entry for a generic version of the antibiotic, which is used to treat infections of the colon and the intestine, including those caused by strains of the staph bacterium that don't respond to more common antibiotics.

Cutler called the stock price drop "a little overblown," because Vancocin attacks infections in such a localized way that proving equivalence is much more difficult than simply proving that the two drugs are equally present in the body.

"It's not absorbed in the digestive process," Cutler said of Vancocin. "It actually passes through the system and cures the infection where it occurs. So you can't just test for blood levels of the drug and assume that it's the same." Instead, generic approval would require a head-to-head clinical trial with Vancocin -- a lengthy and costly process for a company with only $2 million in cash, Akorn's latest public figure.

Wei noted both Viropharma and Lilly have said the manufacturing process for Vancocin is "highly intricate" and involves proprietary technology that may be difficult to reverse engineer.

Cutler argued this aspect was less of a barrier.

"I do imagine that a smart generic company could figure out that manufacturing process. It may take some time, but I do think they can to do it," Cutler said.

Shares of Buffalo Grove, Ill.-based Akorn rose a penny, to $3.90, in afternoon trading on the American Stock Exchange.

 

ViroPharma Selected for NASDAQ Biotechnology Index
Monday November 14, 9:18 am ET

EXTON, Pa., Nov. 14, 2005 (PRIMEZONE) -- ViroPharma Incorporated (NasdaqNM:VPHM - News) today announced that it has been selected to become a member of the NASDAQ Biotechnology Index(R). ViroPharma's inclusion in the index will become effective with the market open on Monday, November 21, 2005.  

liebe viropharma-fans,

also ums kurz zu machen:
der wert ist 2005 gut gelaufen, aber weitere kursgewinne sind 2006 nicht zu erwarten.
also raus damit, wer sie noch hat!

frohe weihnachten!

lilly






 

Viropharma ist wohl wieder ein Thema! Die Angriffe der Konkurrenz blieben aus und Viropharma macht weiterhin fette Gewinne! Außerdem Medikamente in Phase III und Phase II! Und ein KGV von 15, als Biotechunternehmen!!!